Cantor Fitzgerald Forecasts TNGX FY2025 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Tango Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings per share of ($1.39) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Several other equities research analysts have also commented on TNGX. Guggenheim cut their price target on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. B. Riley reduced their target price on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a report on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a research note on Friday, November 8th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $13.14.

Tango Therapeutics Stock Up 8.1 %

Shares of Tango Therapeutics stock opened at $3.08 on Wednesday. The firm’s 50 day moving average is $3.31 and its two-hundred day moving average is $6.64. Tango Therapeutics has a 52 week low of $2.59 and a 52 week high of $13.01. The firm has a market capitalization of $330.85 million, a P/E ratio of -2.61 and a beta of 0.81.

Institutional Trading of Tango Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TNGX. State Street Corp grew its stake in shares of Tango Therapeutics by 26.8% during the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after buying an additional 489,949 shares during the period. Point72 Asset Management L.P. acquired a new position in Tango Therapeutics during the 2nd quarter worth $3,836,000. Geode Capital Management LLC raised its position in shares of Tango Therapeutics by 11.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock valued at $10,538,000 after acquiring an additional 142,710 shares in the last quarter. Walleye Capital LLC acquired a new stake in Tango Therapeutics during the third quarter worth about $1,098,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Tango Therapeutics by 42.5% during the second quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock worth $2,882,000 after acquiring an additional 100,257 shares during the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Insider Activity at Tango Therapeutics

In other news, insider Boxer Capital Management, Llc sold 633,000 shares of Tango Therapeutics stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $6.87, for a total value of $4,348,710.00. Following the sale, the insider now owns 6,690,642 shares of the company’s stock, valued at $45,964,710.54. The trade was a 8.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mace Rothenberg purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were purchased at an average cost of $3.62 per share, with a total value of $36,200.00. Following the completion of the acquisition, the director now directly owns 21,250 shares of the company’s stock, valued at $76,925. This represents a 88.89 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 6.30% of the stock is currently owned by insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.